drugset / Trial / NCT01404923

Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)

NCT01404923 ↗

Phase 4 Completed 436 enrolled Laboratoires Mayoly Spindler
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: * Strategy A = MeteoSpasmyl®, on-demand therapy * Strategy B = standard of care chosen by the physician

Timeline

Start
2009-12
Primary completion
2011-10
Completion
2011-10

Outcome

Met primary endpoint

paper At 6 months, improvement of IBSQoL was greater with ACS than with the usual treatment group (13.8 vs. 8.4; p < 0.0008). PMID 24147869 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Alverine Small molecule — —
Subject simeticone Unknown — —